REGENERON PHARMACEUTICALS, INC. (REGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 2B 4B 6B Q3 '21: 3.5B Q4 '21: 5B Q1 '22: 3B Q2 '22: 2.9B Q3 '22: 2.9B Q4 '22: 3.4B Q1 '23: 3.2B Q2 '23: 3.2B Q3 '23: 3.4B Q4 '23: 3.4B Q1 '24: 3.1B Q2 '24: 3.5B Q3 '24: 3.7B Q4 '24: 3.8B Q1 '25: 3B Q2 '25: 3.7B Q3 '25: 3.8B Q4 '25: 3.9B Q1 '26: 3.6B Q2 '26: 4.3B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

0 900M 1.8B 2.7B Q3 '21: 1.8B Q4 '21: 2.6B Q1 '22: 1.3B Q2 '22: 1.1B Q3 '22: 1.2B Q4 '22: 1.1B Q1 '23: 946.7M Q2 '23: 1B Q3 '23: 1.1B Q4 '23: 972.9M Q1 '24: 751.4M Q2 '24: 1.1B Q3 '24: 1.2B Q4 '24: 990.2M Q1 '25: 591.7M Q2 '25: 1.1B Q3 '25: 1B Q4 '25: 879.9M Q1 '26: 642.9M Q2 '26: 1.3B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

0 800M 1.6B 2.4B Q3 '21: 1.6B Q4 '21: 2.2B Q1 '22: 973.5M Q2 '22: 852.1M Q3 '22: 1.3B Q4 '22: 1.2B Q1 '23: 817.8M Q2 '23: 968.4M Q3 '23: 1B Q4 '23: 1.2B Q1 '24: 722M Q2 '24: 1.4B Q3 '24: 1.3B Q4 '24: 917.7M Q1 '25: 808.7M Q2 '25: 1.4B Q3 '25: 1.5B Q4 '25: 844.6M Q1 '26: 727.2M Q2 '26: 1.3B Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

0 1.5B 3B 4.5B Q3 '21: 3.4B Q4 '21: 2.4B Q1 '22: 2.1B Q2 '22: 564.4M Q3 '22: 628.9M Q4 '22: 1.7B Q1 '23: 1.4B Q2 '23: 1B Q3 '23: 1.1B Q4 '23: 1.1B Q1 '24: 1.5B Q2 '24: 354M Q3 '24: 1.3B Q4 '24: 1.3B Q1 '25: 1B Q2 '25: 1.1B Q3 '25: 1.6B Q4 '25: 1.2B Q1 '26: 1.1B Q2 '26: 813M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

0 1.5B 3B 4.5B Q3 '21: 3.3B Q4 '21: 2.2B Q1 '22: 2B Q2 '22: 410.8M Q3 '22: 486.4M Q4 '22: 1.6B Q1 '23: 1.2B Q2 '23: 909.4M Q3 '23: 938.3M Q4 '23: 838.3M Q1 '24: 1.4B Q2 '24: 173.5M Q3 '24: 1B Q4 '24: 1.1B Q1 '25: 815.8M Q2 '25: 925.4M Q3 '25: 1.4B Q4 '25: 922M Q1 '26: 848.3M Q2 '26: 572.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '20: 115.1M Q2 '20: 117.9M Q3 '20: 113.9M Q1 '21: 110.5M Q2 '21: 110.8M Q3 '21: 113.9M Q1 '22: 113.1M Q2 '22: 114M Q3 '22: 112.8M Q1 '23: 114M Q2 '23: 113.9M Q3 '23: 113.4M Q1 '24: 115.1M Q2 '24: 115.4M Q3 '24: 116.2M Q1 '25: 111.2M Q2 '25: 108.6M Q3 '25: 107.2M Q1 '26: 107.7M Q2 '26: 106M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 25.00 50.00 75.00 Q3 '21: 62.63 Q4 '21: 72.07 Q1 '22: 70.59 Q2 '22: 50.09 Q3 '22: 47.42 Q4 '22: 38.23 Q1 '23: 36.79 Q2 '23: 37.82 Q3 '23: 35.05 Q4 '23: 34.76 Q1 '24: 33.86 Q2 '24: 37.77 Q3 '24: 40.42 Q4 '24: 38.33 Q1 '25: 39.33 Q2 '25: 39.73 Q3 '25: 41.81 Q4 '25: 41.57 Q1 '26: 41.05 Q2 '26: 40.47 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.